Drug Trial Radar · NCT04594681
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
116
Actual
Start
Sep 16, 2020
Primary completion
Aug 26, 2022
Study completion Aug 26, 2022
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety and tolerability after administration of KHK4951 in healthy volunteers and patients with wet age-related macular degeneration.
Conditions
- Healthy Volunteers
- Wet Age-related Macular Degeneration
Interventions
PlaceboDrug
Placebo is administered once daily or three times daily.
KHK4951Drug
KHK4951 is administered once daily or three times daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: Day 1 to Day 43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hakata clinic
Fukuoka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.